强生Centocor公司和先灵葆雅公司联合开发的完全人源化抗TNF-α单克隆抗体golimumab应用了Medarex公司的HuMAb-MouseTM技术,为一种每月1次皮下注射产品,最近已在其全球首个市场——加拿大以Simponi商品名获准上市,其适应证包括与甲氨蝶呤联用治疗中度至重度类风湿性关节炎、单 Golimumab, a fully humanized anti-TNF-α monoclonal antibody developed jointly by Johnson & Johnson Centocor and Schering-Plow, uses Medarex’s HuMAb-MouseTM technology as a subcutaneous injection once a month that has recently been demonstrated in its world’s first market - Canada is listed under the Simponi brand name, its indications include combined with methotrexate in the treatment of moderate to severe rheumatoid arthritis, single